Clinical trial
A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have…
NCT00116909 · OSI Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00116909 |
|---|---|
| Title | A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy |
| Official title | A Phase II Study of Single-Agent OSI-7904L in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed First-Line Therapy |
| Lead sponsor | OSI Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Locally Recurrent or Metastatic Cancer of the Head and Neck, Must Have Failed First-Line Therapy |
| Intervention type | Drug |
| Interventions | OSI 7904L |
| Enrollment | 85 |
| Start date | Aug 1, 2004 |
| Completion | Aug 1, 2005 |
| First posted | Jul 1, 2005 |
| Last update posted | Mar 14, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: